Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Structure Therapeutics Inc. American Depositary Shares (GPCR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/15/2025: GPCR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $76.32
1 Year Target Price $76.32
| 8 | Strong Buy |
| 6 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 43.8% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.13B USD | Price to earnings Ratio - | 1Y Target Price 76.32 |
Price to earnings Ratio - | 1Y Target Price 76.32 | ||
Volume (30-day avg) 14 | Beta -1.97 | 52 Weeks Range 13.22 - 45.37 | Updated Date 07/15/2025 |
52 Weeks Range 13.22 - 45.37 | Updated Date 07/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.58 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -17.24% | Return on Equity (TTM) -22.85% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 296699190 | Price to Sales(TTM) - |
Enterprise Value 296699190 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -13.46 | Shares Outstanding 57536800 | Shares Floating 146219869 |
Shares Outstanding 57536800 | Shares Floating 146219869 | ||
Percent Insiders 2.74 | Percent Institutions 101.15 |
Upturn AI SWOT
Structure Therapeutics Inc. American Depositary Shares
Company Overview
History and Background
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapeutics for chronic diseases with significant unmet needs. Founded in 2016, the company leverages its structure-based drug discovery platform to design and develop differentiated product candidates targeting validated G protein-coupled receptors (GPCRs).
Core Business Areas
- GPCR-Targeted Drug Discovery: Focuses on developing oral small molecule therapeutics that selectively target GPCRs to treat a range of chronic diseases, primarily in metabolic and pulmonary indications.
Leadership and Structure
Raymond Stevens is the Founder, CEO, and Board Director. The company has a leadership team with experience in drug discovery, development, and commercialization. Structure is organized into research, development, and administrative functions.
Top Products and Market Share
Key Offerings
- GSBR-1290 (Oral GLP-1R Agonist): An oral small molecule GLP-1 receptor (GLP-1R) agonist being developed for the treatment of type 2 diabetes and obesity. Currently in Phase 2 clinical trials. Market share is currently 0 due to developmental stage. Competitors include Novo Nordisk (Semaglutide), Eli Lilly (Tirzepatide) in injectable form and Pfizer and others developing oral GLP-1 therapies.
- ANPA-0073 (Oral Apelin Receptor Agonist): An oral Apelin receptor (APJR) agonist in development for idiopathic pulmonary fibrosis (IPF). Currently in Phase 1 trials. Market share is currently 0 due to developmental stage. Boehringer Ingelheim, Roche/Genentech, Bristol Myers Squibb are competitors in IPF.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with companies focusing on developing innovative therapies for various diseases. The metabolic and pulmonary disease areas are experiencing significant growth due to the rising prevalence of diabetes, obesity, and pulmonary diseases.
Positioning
Structure Therapeutics aims to differentiate itself through its structure-based drug discovery platform, focusing on oral small molecule therapeutics targeting GPCRs. This approach aims to provide convenient and effective treatment options compared to injectable therapies.
Total Addressable Market (TAM)
The combined TAM for diabetes, obesity, and IPF is estimated to be over $100 billion. Structure Therapeutics is positioning itself to capture a portion of this market with its oral therapeutics targeting these indications.
Upturn SWOT Analysis
Strengths
- Proprietary Structure-Based Drug Discovery Platform
- Experienced Management Team
- Strong Pipeline of Oral GPCR-Targeted Therapeutics
- Focus on High Unmet Needs
Weaknesses
- Clinical Stage Company with No Approved Products
- Dependence on Successful Clinical Trial Outcomes
- High Cash Burn Rate Associated with Drug Development
- Limited Commercialization Experience
Opportunities
- Potential to Disrupt Injectable Therapy Markets with Oral Alternatives
- Expansion of Pipeline into Additional GPCR Targets
- Strategic Partnerships and Collaborations
- Positive Clinical Trial Results Driving Market Value
Threats
- Clinical Trial Failures
- Competition from Established Pharmaceutical Companies
- Regulatory Hurdles and Delays
- Patent Expiration and Generics
Competitors and Market Share
Key Competitors
- NVO
- LLY
- PFE
- VRTX
Competitive Landscape
Structure Therapeutics is a clinical-stage biopharmaceutical company and currently has no drugs on the market. Competitors are much larger and already have multiple drugs on the market.
Growth Trajectory and Initiatives
Historical Growth: Structure Therapeutics's growth has been primarily driven by pipeline advancement and increased R&D spending.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates project significant revenue growth upon commercialization of GSBR-1290 and other pipeline assets.
Recent Initiatives: Recent initiatives include advancing GSBR-1290 into Phase 2b clinical trials, initiating Phase 1 trials for ANPA-0073, and expanding the drug discovery platform.
Summary
Structure Therapeutics is a clinical-stage biopharmaceutical company with a promising structure-based drug discovery platform. The company's lead asset, GSBR-1290, has the potential to disrupt the diabetes and obesity market. However, the company faces risks associated with clinical trial outcomes and competition from established pharmaceutical companies. Successful clinical trials and strategic partnerships are crucial for the company's future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Structure Therapeutics Inc. American Depositary Shares
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2023-02-03 | CEO & Director Dr. Raymond C. Stevens Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 183 | Website https://structuretx.com |
Full time employees 183 | Website https://structuretx.com | ||
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671, which is in preclinical trial to treat obesity; ANPA-0073, an oral small molecule agonist targeting the apelin, which is phase 2 ready for selective weight loss or muscle-sparing weight loss; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis. In addition, it develops programs, including glucose-dependent insulinotropic polypeptide receptor (GIPR) program, which identified multiple GIPR agonist, dual GLP-1R/GIPR agonist, and GIPR antagonist hits for small molecule GIPR modulation that has the potential to provide a treatment in obesity; and GCG program, which identified multiple GCG receptor (GCGR) agonist and dual GLP-1R/GCGR agonist hits for small molecule GCGR modulation. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.